Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer's Disease-Modifying Therapy.

ABSTRACT:

Background

Recently, two monoclonal antibodies that lower amyloid plaques have shown promising results for the treatment of Mild Cognitive Impairment (MCI) and mild dementia due to Alzheimer's disease (AD). These treatments require the identification of cognitively impaired older adults with biomarker evidence of AD pathology using CSF biomarkers or amyloid-PET. Previous studies showed plasma biomarkers (plasma Aβ42/Aβ40 and p-tau181) and hippocampal volume from structural MRI correlated with brain amyloid pathology. We hypothesized plasma biomarkers with hippocampal volume would identify patients who are suitable candidates for disease-modifying therapy.

Objectives

To evaluate the performance of plasma AD biomarkers and hippocampal atrophy to detect MCI or AD with amyloid p

SUBMITTER: Manjavong M 

PROVIDER: S-EPMC11436390 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature